Abstract The invention relates to the use of hepatocyte and keratinocyte growth factors for stimulating the proliferation and motility of corneal cells in vivo and in vitro. Also disclosed is the use of these factors for maintaining the viability of corneal cells during or after ocular surgery and during corneal preservation in storage medium prior to transplant. Polymerase chain reaction amplification has demonstrated that corneal epithelial and endothelial cells in vitro and ex vivo corneal epithelium produce messenger RNA coding for hepatocyte growth factor, hepatocyte growth factor receptor, keratinocyte growth factor, and keratinocyte growth factor receptor. Several growth factors were found to inhibit the differentiation of corneal epithelial cells as measured by decreased expression of keratin K3. Methods for treating ocular dry eye diseases are presented.
A method of inhibiting corneal epithelial cell differentiation comprising contacting a corneal cell with an amount of a growth factor selected from the group consisting of hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) effective to inhibit corneal cell differentiation.
Claim 2
Independent Claim
41 words
A method of inhibiting corneal epithelial cell differentiation comprising contacting a corneal cell with an amount of a growth factor selected from the group consisting of hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) effective to inhibit corneal cell differentiation.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein the dry eye ocular disease is keratoconjunctivitis sicca.
Claim 4
Dependent Claim
18 words
The method of claim 1 wherein the cell is contacted sequentially with two growth factors from said group.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein the corneal cell is in a mammal.
Claim 6
Dependent Claim
17 words
The method of claim 4 wherein the corneal cell differentiation is associated with dry eye ocular disease.
Claim 7
Dependent Claim
17 words
The method of claim 5 wherein the dry eye ocular disease is further identified as keratoconjunctivitis sicca.
Claim 8
Dependent Claim
21 words
The method of claim 1 wherein the cell is contacted simultaneously with hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF).
Claim 9
Dependent Claim
16 words
The method of claim 6 further including combining the growth factor with a timed release system.
Claim 10
Dependent Claim
19 words
The method of claim 8 wherein the timed release delivery system is a biodegradable polymer encapsulating the growth factor.
Claim 11
Dependent Claim
12 words
The method of claim 9 wherein the biodegradable polymer is a microcapsule.
Claim 12
Dependent Claim
12 words
The method of claim 5 further comprising topically administering the growth factor.